Pfizer Enters $226 Million China/Asia Deal for Basilea's Anti-Fungal Drug
publication date: Dec 4, 2017
Pfizer signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug developed by Swiss pharma Basilea. Previously, Pfizer acquired rights for Cresemba in Europe, Russia, Turkey and Israel. In the latest deal, Pfizer in-licensed rights for China (including Hong Kong and Macao) and sixteen countries in the Asia Pacific region. Isavuconazole is an antifungal aimed at life-threatening invasive mold infections. Pfizer will develop, manufacture and commercialize isavuconazole in China and the Asia Pacific region. More details....
Stock Symbols: (NYSE: PFE) (SIX: BSLN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.